Abstract:OBJECTIVE:To investigate the effects of budesonide (BUD) used in an early phase or delayed phase on the airway inflammation and airway remodeling in ovalbumin (OVA) sensitized and challenged mice. METHODS:Forty mice were divided into 5 groups (8 in each group) including group A [ovalbumin (OVA) sensitized/challenged mice], group B (saline sensitized/challenged mice), group C (OVA sensitized/challenged mice treated by BUD in the early phase), group D (OVA-sensitized/challenged mice treated by BUD in the late phase) and group E (OVA-sensitized/challenged mice following saline challenge for 18 days). Mice were sensitized on days 0 and 14 by OVA and challenged from days 24 to 41 by OVA repeatedly to establish a murine model of asthma characterized by airway inflammation and airway remodeling. To assess the effects of BUD on the development of airway remodeling and on established airway remodeling, animals were treated with aerosolized BUD (0.5 mg/ml per day) from day 1 before OVA challenge (group C) and from day 18 following first OVA challenge (group D). The outcome measurements included airway inflammatory indices, eosinophils (EOS) count and amount of collagen deposition around the bronchus, area of airway smooth muscle, the degree of mucus secretion in the lumens and depth of airway smooth muscle (ASM) in different grade bronchus by HE, PAS and Masson's staining. The bronchoalveolar lavage fluids (BALF) were assayed for IL-5 and IFN-gamma levels. RESULTS:In repeatedly OVA-challenged mice (group A), EOS counts in BALF increased significantly [(57.460 +/- 11.060) x 10(4)/ml] when compared with group B [(0.050 +/- 0.020) x 10(4)/ml, P < 0.01]. The IL-5 level increased significantly [(52.9 +/- 2.8) pg/ml vs (16.8 +/- 1.5) pg/ml, < 0.01] and IFN-gamma decreased significantly [(39.5 +/- 3.2) pg/ml vs (63.8 +/- 3.3) pg/ml, < 0.01]. Repeatedly OVA-challenged animals (group A) also developed an increase in EOS counts around bronchus [(1 018 +/- 118)/mm(2)] when compared with group B [(7 +/- 3)/mm(2), < 0.01], goblet cell hyperplasia [(46.0 +/- 5.8)% vs (1.8 +/- 0.5)%, < 0.01] and mucus hypersecretion [(score 2.98 +/- 0.23) vs (score 0.13 +/- 0.06), < 0.01], airway smooth muscle hypertrophy [(30.2 +/- 2.2)/microm(2)/microm vs (13.1 +/- 1.0) microm(2)/microm, < 0.01], enhanced collagen deposition of reticular basement membrane (RBM) [(24.9 +/- 1.3) microm(2)/microm vs (4.3 +/- 0.6) microm(2)/microm, all < 0.01]. Early treatment with BUD significantly reduced EOS counts in BALF [(7.140 +/- 1.250) x 10(4)/ml] as compared with group A [(57.460 +/- 11.060) x 10(4)/ml], < 0.01]. Early BUD treatment also significantly reduced EOS counts around bronchus [(214 +/- 26)/mm(2)], allergen-induced structural changes including goblet cell hyperplasia [(16.1 +/- 2.5)%] and mucus hypersecretion (1.10 +/- 0.15), airway smooth muscle hypertrophy [(14.0 +/- 0.7) microm(2)/microm], and RBM collagen deposition [(12.6 +/- 1.3) microm(2)/microm]. In group E, EOS counts in BALF [(1.250 +/- 0.330) x 10(4)/ml] were decreased significantly when compared with group A (< 0.01), but airway smooth muscle hypertrophy [(32.4 +/- 1.8) microm(2)/microm], and RBM collagen deposition [(22.8 +/- 1.7) microm(2)/microm] showed no reduction as compared with group A (all P > 0.05). Delayed BUD treatment significantly reduced EOS counts in BALF [(0.800 +/- 0.170) x 10(4)/ml], goblet cell hyperplasia [(29.3 +/- 4.3)%] and mucus hypersecretion (1.63 +/- 0.17, < 0.05 or < 0.01), but had no effects on OVA-induced airway smooth muscle hypertrophy [(30.1 +/- 1.8) microm(2)/microm] and RBM collagen deposition [(23.7 +/- 1.4) microm(2)/microm] as compared with group A (P > 0.05). CONCLUSIONS:Early treatment with BUD inhibited the development of airway inflammation of airway remodeling. However, delayed use with BUD inhibited airway inflammation, but only partially reversed airway remodeling in a murine model of asthma.

Preventive effect of budesonide on inflammatory signal transduction system of allergic asthma model

The Expression of STAT5b Mrna and IL-4 Mrna of Mononuclearcell in Blood of a Rat Model of Asthma and the Modulatory Effect of Budesonide

Altered Frequency of NK Cells and Treg Cells by <i>Astragalus</i> Polysaccharide Combined with Budesonide in Asthma Model Mice

Effect of Budesonide on expression of Janus protein tyrosin kinase 1 and interleukin-4 in mice with asthma

The effects of budesonide on the expressions of TGF-β/Smad signaling pathways in asthmatic mice

Dynamic Changes in Airway Hyperresponsiveness As a Result of Allergen and Therapeutic Effects of Budesonide in Rats

Effect of Budesonide on Dendritic Cells in Asthmatic Mice

Effects of Andrographolide and Budesonide on the Expressions of Interleukin-17 and Interleukin-23 in Asthmatic Mice Model

The effects of intranasal budesonide on allergen-induced production of interleukin-5 and eotaxin, airways, blood, and bone marrow eosinophilia, and eosinophil progenitor expansion in sensitized mice.

Comparison of improvement of two kinds of preventative administration of inter-leukin-27 on airway inflammation and impaired phosphorylation of STAT1 in asthma mice

The impact of bacterial lysate on asthma prevention in mouse

Effects of Budesonide on Airway Inflammation and Airway Remodeling in the Ovalbumin Sensitized and Challenged Mice

Effect of Andrographolide on Expressions of Inflammatory Cells, Interleukin-12 and Interleukin-13 in Bronchoalveolar Larage Fluid of Asthmatic Mice Model

[Effect of Exposure to Allergen Through Different Duration on a Rat Asthmatic Model].

Effects of Budesonide and Bacillus Calmette-Guerin on Damages of Type Ⅱ Alveolar Epithelial Cell in Asthmatic Mice Model

Protective Effects of Astragaloside IV Combined with Budesonide in Bronchitis in Rats by Regulation of Nrf2/Keap1 Pathway.

Effect of Inhaled Budesonide on Interleukin-4 and Interleukin-6 in Exhaled Breath Condensate of Asthmatic Patients.

Preventative Administration of Il-27 Improves Airway Inflammation of Ovalbumin - Induced Asthma Mice Model Via Both Stat1 and Gadd45 Gamma/P38mapk Pathways

Effects of Budesonide Plus Vitamin AD on Children with Bronchial Asthma and the Effect on Serum IgE and C-reactive Protein

Effect of Bacteria Lysates and 1,25-Dihydroxy Vitamin D3 on Airway Inflammation in Asthmatic Mice Models

Study Effect of Vitamin D on the Immunopathology Responses of the Bronchi in Murine Model of Asthma